MA32388B1 - Immunomodulation par des inhibiteurs d'iap - Google Patents

Immunomodulation par des inhibiteurs d'iap

Info

Publication number
MA32388B1
MA32388B1 MA33406A MA33406A MA32388B1 MA 32388 B1 MA32388 B1 MA 32388B1 MA 33406 A MA33406 A MA 33406A MA 33406 A MA33406 A MA 33406A MA 32388 B1 MA32388 B1 MA 32388B1
Authority
MA
Morocco
Prior art keywords
methods
inhibitors
prevention
immunomodulation
ipa
Prior art date
Application number
MA33406A
Other languages
Arabic (ar)
English (en)
Inventor
Brant G Firestone
Glenn Dranoff
Leigh Zawel
Christopher S Straub
Michael Dougan
Original Assignee
Novartis Ag
Dana Farber Cancer Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40823320&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32388(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag, Dana Farber Cancer Inst Inc filed Critical Novartis Ag
Publication of MA32388B1 publication Critical patent/MA32388B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des adjuvants immunitaires contenant des inhibiteurs d'iap, comprenant des mimétiques de smac. L'invention concerne en outre des compositions pharmaceutiques et des vaccins contenant un inhibiteur d'iap et un antigène. La présente invention concerne en outre des procédés d'amélioration d'une réponse immunitaire par administration d'un inhibiteur d'iap, des procédés de traitement ou de prévention du cancer, des procédés de traitement ou de prévention des infections, des procédés de traitement de troubles auto-immuns, et des procédés de potentialisation de la production de cytokine ou d'anticorps.
MA33406A 2008-05-16 2010-12-08 Immunomodulation par des inhibiteurs d'iap MA32388B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5394708P 2008-05-16 2008-05-16
PCT/US2009/043874 WO2009140447A1 (fr) 2008-05-16 2009-05-14 Immunomodulation par des inhibiteurs d’iap

Publications (1)

Publication Number Publication Date
MA32388B1 true MA32388B1 (fr) 2011-06-01

Family

ID=40823320

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33406A MA32388B1 (fr) 2008-05-16 2010-12-08 Immunomodulation par des inhibiteurs d'iap

Country Status (17)

Country Link
US (4) US9750729B2 (fr)
EP (3) EP3701947A1 (fr)
JP (3) JP5779091B2 (fr)
KR (1) KR20110022608A (fr)
CN (1) CN102099035A (fr)
AU (1) AU2009246347A1 (fr)
BR (1) BRPI0912692A2 (fr)
CA (1) CA2724720A1 (fr)
CL (1) CL2009001195A1 (fr)
EA (1) EA201071316A1 (fr)
ES (2) ES2882855T3 (fr)
IL (1) IL209203A0 (fr)
MA (1) MA32388B1 (fr)
MX (1) MX2010012231A (fr)
TW (1) TW201006834A (fr)
WO (1) WO2009140447A1 (fr)
ZA (1) ZA201008176B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7772177B2 (en) 2005-05-18 2010-08-10 Aegera Therapeutics, Inc. BIR domain binding compounds
JP2009512719A (ja) 2005-10-25 2009-03-26 アエゲラ セラピューティクス インコーポレイテッド Ｉａｐｂｉｒドメイン結合化合物
JP4995211B2 (ja) * 2008-09-29 2012-08-08 キヤノン株式会社 電子写真画像形成装置
RU2567544C2 (ru) 2010-02-12 2015-11-10 Фармасайенс Инк. Bir домен iap связывающие соединения
JP6785653B2 (ja) 2013-06-25 2020-11-18 ザ・ウォルター・アンド・エリザ・ホール・インスティテュート・オブ・メディカル・リサーチ 細胞内感染の処置方法
US10441654B2 (en) 2014-01-24 2019-10-15 Children's Hospital Of Eastern Ontario Research Institute Inc. SMC combination therapy for the treatment of cancer
JP2019514878A (ja) * 2016-04-20 2019-06-06 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Ｒｉｐｋ２阻害剤を含むコンジュゲート
CN106496213B (zh) * 2016-09-30 2019-08-20 东南大学 Lcl161前药及其制备方法和应用
US11639354B2 (en) * 2018-07-31 2023-05-02 Fimecs, Inc. Heterocyclic compound
EP3886842A1 (fr) 2018-11-26 2021-10-06 Debiopharm International SA Traitement combiné d'infections au vih
CA3151770A1 (fr) 2019-09-25 2021-04-01 Silvano BRIENZA Schemas posologiques pour le traitement de patients presentant un carcinome localement avance des cellules squameuses

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2610934B1 (fr) * 1987-02-13 1989-05-05 Adir Nouveaux derives peptidiques a structure polycyclique azotee, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6133437A (en) * 1997-02-13 2000-10-17 Apoptogen, Inc. Modulation of IAPs for the treatment of proliferative diseases
US7687465B2 (en) * 2003-04-11 2010-03-30 Kraeftens Bekaempelse Therapeutic cancer vaccine
EP2311851A3 (fr) * 2004-02-04 2011-05-25 Vertex Pharmaceuticals Incorporated Inhibitoren der Serinproteasen, insbesondere der HCV-NS3-NS4A-Protease
CN1926118A (zh) 2004-03-01 2007-03-07 德克萨斯大学董事会 二聚的小分子细胞凋亡增强剂
CA2558615C (fr) * 2004-03-23 2013-10-29 Genentech, Inc. Inhibiteurs azabicyclo-octane de l'iap
ME02125B (fr) * 2004-04-07 2013-04-30 Novartis Ag Inhibiteurs d'iap
JP4997970B2 (ja) 2004-05-02 2012-08-15 株式会社セガ ゲームシステム
BRPI0607988A2 (pt) 2005-02-25 2009-10-27 Tetralogic Pharmaceuticals composto, composição farmacêutica, e método para induzir apoptose em uma célula
KR20080080131A (ko) 2005-12-20 2008-09-02 노파르티스 아게 Ｉａｐ-억제제와 탁산의 조합물
US20100056495A1 (en) * 2006-07-24 2010-03-04 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
PE20110218A1 (es) * 2006-08-02 2011-04-01 Novartis Ag DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
RU2009117701A (ru) * 2006-10-12 2010-11-20 Новартис АГ (CH) Производные пирролидина в качестве ингибиторов iap
EP2076778A2 (fr) 2006-10-19 2009-07-08 Novartis AG Composés organiques
CA2670498A1 (fr) * 2006-11-28 2008-06-05 Novartis Ag Combinaison d'inhibiteurs de iap et d'inhibiteurs de flt3
WO2008077969A1 (fr) 2006-12-26 2008-07-03 Arcelik Anonim Sirketi Lave-linge/sèche-linge avec grandeur de sortie provenant du capteur d'humidité entrée sélectivement vers l'unité de commande
WO2008109057A1 (fr) * 2007-03-02 2008-09-12 Dana-Farber Cancer Institute, Inc. Composés organiques et leurs utilisations

Also Published As

Publication number Publication date
CA2724720A1 (fr) 2009-11-19
US20170368047A1 (en) 2017-12-28
WO2009140447A1 (fr) 2009-11-19
EP2296650A1 (fr) 2011-03-23
CN102099035A (zh) 2011-06-15
CL2009001195A1 (es) 2010-06-11
AU2009246347A1 (en) 2009-11-19
ES2882855T3 (es) 2021-12-02
EP2296650B1 (fr) 2020-05-06
US11382905B2 (en) 2022-07-12
JP2016094429A (ja) 2016-05-26
ZA201008176B (en) 2011-08-31
JP5779091B2 (ja) 2015-09-16
JP5986655B2 (ja) 2016-09-06
US20110135691A1 (en) 2011-06-09
MX2010012231A (es) 2011-02-18
IL209203A0 (en) 2011-01-31
JP2011524339A (ja) 2011-09-01
ES2791957T3 (es) 2020-11-06
KR20110022608A (ko) 2011-03-07
JP6030739B2 (ja) 2016-11-24
BRPI0912692A2 (pt) 2017-03-21
EP2698158A1 (fr) 2014-02-19
TW201006834A (en) 2010-02-16
JP2015129170A (ja) 2015-07-16
EA201071316A1 (ru) 2011-06-30
US9750729B2 (en) 2017-09-05
EP2698158B1 (fr) 2021-06-30
US20220296581A1 (en) 2022-09-22
US10786491B2 (en) 2020-09-29
EP3701947A1 (fr) 2020-09-02
US20200345714A1 (en) 2020-11-05

Similar Documents

Publication Publication Date Title
MA32388B1 (fr) Immunomodulation par des inhibiteurs d'iap
MX2010005871A (es) Anticuerpos al antigeno de pcrv de pseudomonas aeruginosa.
MX2012010793A (es) Composiciones y metodos para la eliminacion de biopeliculas.
WO2012045001A3 (fr) Anticorps dirigés contre le virus de la grippe, immunogènes et leurs utilisations
CY1115235T1 (el) Συνθεσεις και μεθοδοι ενισχυσης του ανοσοποιητικου συστηματος
BR112013020500A2 (pt) anticorpo isolado, recombinante ou purificado
ATE426412T1 (de) Adjuvante influenza-vakzine
MX2010008035A (es) Composicion que comprende anticuerpo que se fija al dominio ii de her2, y sus variantes acidas.
CY1113640T1 (el) Μεθοδοι για την θεραπευτικη αγωγη ρευματοειδους αρθριτιδας
MX2016001555A (es) Modulocinas basadas en dominio sushi de interleucina-15 (il-15) y receptor alfa de interleucina-15 (il-15ra).
EA200800355A1 (ru) Нейтрализующие антитела человека против b7rp1
EA200970916A1 (ru) Соединения 5,6-дигидро-1н-пиридин-2-она
UA118332C2 (uk) Білок, що зв'язує антиген cd27l
EA201391170A1 (ru) Терапевтическое средство на основе дрожжей для лечения хронического гепатита b
WO2008033966A3 (fr) Particules de réplicon d'alphavirus correspondant à des antigènes de protéines utilisées en qualité d'adjuvants immunologiques
WO2014205199A3 (fr) Compositions et méthodes de potentialisation de la réponse immunitaire, de stimulation de l'immunothérapie et d'augmentation de la puissance d'un vaccin
WO2008134643A3 (fr) Antigènes de trypanosome, compositions de vaccins et procédés associés
WO2009114560A3 (fr) Compositions et procédés pour le diagnostic et le traitement d’une infection à cytomégalovirus
MX2012001495A (es) Polipeptidos de porphyromonas gingivalis.
WO2007150008A3 (fr) Polypeptides issus du virus de la peste porcine africaine utilisés en tant que vaccins à usage préventif et thérapeutique
WO2016020702A8 (fr) Anticorps anti-ténascine-c et utilisations
FR2897063B1 (fr) Polypeptides reconnus par des anticorps anti-trichinella, et leurs applications.
WO2015031778A3 (fr) Compositions et méthodes pour le traitement ou la prévention de la tuberculose
EA201391199A1 (ru) Композиции из hyr1-производных и способы лечения ими
PH12018501646A1 (en) Compositions and methods for treating infections